
    
      This is a Phase 2, randomized, multi-center, multi-dose study. Sixty subjects with irritable
      bowel syndrome with constipation who are between the ages of 18 and 65, inclusive, will be
      enrolled. The entire duration of the study may be up to 43 days (from Screening to the post
      end-of-study [EOS] visit telephone call).
    
  